Dr. Hans Arwidsson, President & CEO
Dr. Arwidsson is an executive with broad cross-functional experience from the pharmaceutical industry. He has extensive experience from line and project management positions in R&D, Marketing and Operations in Astra and AstraZeneca (1984-2001), where he got deep insights in all parts of the pharmaceutical product life cycle. As the CEO of LipoCore Holding AB (2001-2003), a drug delivery company in Stockholm, he developed the company´s sales and business development functions. Arwidsson is a pharmacist by training and holds a M.Sc. (1984) and a Ph.D. (1991) in pharmaceutical sciences from the University of Uppsala as well as a MBA from Stockholm School of Economics (1996).
Dr. Anna-Karin Maltais, CSO, Vice President R&D
Dr. Maltais is an immunologist by training and holds a Ph.D. in Immunobiology from the Karolinska Institute, where she focused on vaccine adjuvants and vaccine delivery. She has previously worked as Vice President, Corporate Development at Cyto Pulse Sciences Inc., a U.S. company focusing on vaccine administration by electroporation. Dr. Maltais has been managing clinical trials of new vaccines for several years and has solid experience in vaccine development. She has been employed at Eurocine Vaccines as Business Development Manager since 2011 and is the Head of Research and Development (Chief Scientific Officer, CSO) since September of 2012.
Sandra Jeldes Granstrand, Senior Project Leader, CMC, Chemistry Manufacturing and Control
Sandra Jeldes Granstrand, graduated Master of Engineering from Royal Institute of Technology, KTH, specialized in Bio-Medical Technology, has a solid background managing larger studies and projects. Previously working as Deputy Head of Laboratory and CMC at Newron, where she had the full responsibility for the laboratory work and also all external contacts with CRO/CMO, including QA. In her role at Eurocine Vaccines, Sandra is responsible for all development within the area, including quality procedures and the specifics around designing a nasal vaccine product.
Board of Directors
Mr Michael Wolff Jensen, Chairman of the Board
Michael Wolff Jensen is a lawyer and has previously served as CFO in public traded companies, Genmab A/S and LifeCycle Pharma A/S, with responsibility for investor relations and legal issues. He has extensive experience as a non-executive Director of both private and public listed companies and company law in connection with financing, IPO and licensing. Today he is chairman and consultant CFO of Ascendis Pharma A/S and legal adviser to DONG Energy Renewables.